

# AngioTheraGnostics

You can find me at  
[gabriela@angiotheragnostics.com](mailto:gabriela@angiotheragnostics.com)

**[www.angiotheragnostics.com](http://www.angiotheragnostics.com)**



# Focus

Development of New Drugs and Biomarkers to prevent Cancer Therapeutic Resistance.

# The facts



## **Antiangiogenics**

are used to treat several types of prevalent cancer.

### **Kidney cancer 6<sup>th</sup> and 8<sup>th</sup>**

most common cancer in men and in women.

**Liver cancer 83%** of the estimated new cancer cases worldwide.

### **Colorectal cancer 3<sup>rd</sup> and 2<sup>nd</sup>**

most common cancer in men and in women.

**Ovarian Cancer** and **Neuroendocrine cancer.**

## **Cost estimation**

**\$ 125,000 (vo)-\$ 164,000 (iv)**

total cost of treatment p/y p/p.

**Increases to \$ 200,000 (vo) and \$ 262,400 (iv)**

due to the lack of guidelines after the 1st line of treatment.

## **Attractive market**


**18.0 billion \$**

Global market value for antiangiogenics.

**>10 billion \$/year**

Sales of antiangiogenics

# Resistance to Antiangiogenic therapy



**Renal cell carcinoma**



**Initial response to sunitinib**



**Regrowth tumor**

# Problem


- Most patients develop resistance to antiangiogenic therapies.
- There is no guidance after the 1<sup>st</sup> line of treatment.

# Our technology


We have identified a **new therapeutic target with a patient selection biomarker.**

# Target identification


in vivo PODX models



RNA levels





IHQ



# Pre-clinical Proof of Concept

## Efficacy



Genetic and Pharmacologic inhibition of RF-1 prevent resistance in RCC tumors




# Problem

- Most patients develop resistance to antiangiogenic therapies.
- **There is no guidance after the 1<sup>st</sup> line of treatment.**


# RF-1 as a new biomarker

with patient selection capacity


IHQ in tissue samples




ELISA in plasma samples



# Potential Market & Business Opportunity



# Potential Market & Business Opportunity



# Potential Benefits

New therapeutic drug with a patient selection biomarker



## **Cancer patients resistant to AA**

- Finding a solution for a medical need in patients with advanced cancer.
- Finding the right treatment will improve the life expectancy and outcomes in cancer patients.
- Reducing the risk of toxicity hence improving quality of life.

## **Public health systems**

Decrease care cost for cancer patients.

# AngioTheraGnostics Findings



## **Novel target**

Innovative anti-cancer therapeutic target that we have recently discovered.


## **Novel mechanism of action**

RF-1 is functionally involved in the development of AA resistance.

We have 1 lead candidate to inhibit RF-1.

## **New biomarker**

Patient selection capacity (validated in human samples).



# What we want to do?

## **Spin-off creation**

To increase the value of our products.

## **Develop a new drug**

To prevent AA resistance and continue regulatory roadmap.

## **A new diagnostic kit**

To identify who would benefit from the target inhibition.

# AtG progress co-development process



Define a **new target**

Find a **molecule active** against your target

Desing a **new drug** against your target

- Safety
- Efficacy
- Quality of product



# Looking for financing and investors



To drive our scientific ideas from discovery research to clinical stages testing and market approval.

# Directive Board



**Oriol Casanovas, PhD.**

Group leader

Scientific Expert in  
Oncology and Angiogenesis  
Future CSO



**Gabriela Jiménez, PhD.**

Sc Project Manager

Entrepreneur and Scientist  
Future CEO & Regulatory



**Ramón Salazar, MD PhD.**

Head of Medical Oncology at ICO

Clinical Oncology Expert  
Future CMO

# Thank you for your time

**Any questions?**

You can find me at

**[gabriela@angiotheragnostics.com](mailto:gabriela@angiotheragnostics.com)**

